国药一致
(000028)
| 流通市值：123.24亿 | | | 总市值：143.48亿 |
| 流通股本：4.78亿 | | | 总股本：5.57亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 36,796,598,397.42 | 18,293,519,382.49 | 74,378,494,389.57 | 56,466,354,478.37 |
| 营业收入 | 36,796,598,397.42 | 18,293,519,382.49 | 74,378,494,389.57 | 56,466,354,478.37 |
| 二、营业总成本 | 35,955,918,659.01 | 17,881,473,183.98 | 73,017,475,226.77 | 55,384,596,098.97 |
| 营业成本 | 32,864,811,704.71 | 16,401,114,250.87 | 66,129,208,570.94 | 50,326,326,124.65 |
| 税金及附加 | 93,371,344.03 | 44,705,164.1 | 189,627,779.42 | 141,929,922.36 |
| 销售费用 | 2,436,281,242.55 | 1,170,730,419.96 | 5,360,350,644.71 | 3,940,293,176.93 |
| 管理费用 | 466,644,282.14 | 220,747,505.41 | 1,074,310,777.48 | 773,745,139.26 |
| 研发费用 | 11,631,570.23 | 5,922,554.39 | 24,553,709.11 | 19,243,795.36 |
| 财务费用 | 83,178,515.35 | 38,253,289.25 | 239,423,745.11 | 183,057,940.41 |
| 其中:利息费用 | 91,098,772.3 | 43,629,630.28 | 258,301,906.01 | 198,555,409.74 |
| 其中:利息收入 | 27,390,711.07 | 15,296,092.39 | 58,523,377.05 | 46,615,543.97 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | - | - | -20,675,083.9 | 3,149,334.95 |
| 加:投资收益 | 136,126,440.88 | 79,518,923.04 | 241,793,080.58 | 254,930,911.72 |
| 资产处置收益 | 4,116,939.6 | 997,525.16 | 11,871,648.1 | 6,760,479.35 |
| 资产减值损失(新) | -4,694,534.61 | -1,791,062.26 | -994,531,638.52 | -10,762,327.64 |
| 信用减值损失(新) | -89,044,367.74 | -63,856,766 | -99,325,818.13 | -46,925,729.76 |
| 其他收益 | 39,312,260.63 | 12,223,397.25 | 73,326,930.18 | 55,533,874.21 |
| 四、营业利润 | 926,496,477.17 | 439,138,215.7 | 573,478,281.11 | 1,344,444,922.23 |
| 加:营业外收入 | 10,192,652.43 | 6,567,976.62 | 29,365,873.55 | 21,912,083.23 |
| 减:营业外支出 | 18,575,827.27 | 7,379,327.71 | 27,374,717.34 | 9,893,735.41 |
| 五、利润总额 | 918,113,302.33 | 438,326,864.61 | 575,469,437.32 | 1,356,463,270.05 |
| 减:所得税费用 | 205,519,499.88 | 90,649,557.81 | 338,465,910.83 | 260,793,959.76 |
| 六、净利润 | 712,593,802.45 | 347,677,306.8 | 237,003,526.49 | 1,095,669,310.29 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 712,593,802.45 | 347,677,306.8 | 237,003,526.49 | 1,095,669,310.29 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 665,907,312.44 | 327,998,492.13 | 642,493,449.76 | 1,065,542,103.97 |
| 少数股东损益 | 46,686,490.01 | 19,678,814.67 | -405,489,923.27 | 30,127,206.32 |
| 扣除非经常损益后的净利润 | 642,861,567.03 | 317,427,384.37 | 581,177,195.97 | 1,024,138,901.32 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 1.2 | 0.59 | 1.15 | 1.91 |
| (二)稀释每股收益 | 1.2 | 0.59 | 1.15 | 1.91 |
| 八、其他综合收益 | -36,254.21 | - | -15,541,136.14 | -13,914.59 |
| 归属于母公司股东的其他综合收益 | -36,254.21 | - | -9,315,967.72 | -13,914.59 |
| 九、综合收益总额 | 712,557,548.24 | 347,677,306.8 | 221,462,390.35 | 1,095,655,395.7 |
| 归属于母公司股东的综合收益总额 | 665,871,058.23 | 327,998,492.13 | 633,177,482.04 | 1,065,528,189.38 |
| 归属于少数股东的综合收益总额 | 46,686,490.01 | 19,678,814.67 | -411,715,091.69 | 30,127,206.32 |
| 公告日期 | 2025-08-30 | 2025-04-25 | 2025-04-08 | 2024-10-29 |
| 审计意见(境内) | | | 标准无保留意见 | |